Last €0.52 EUR
Change Today 0.00 / 0.00%
Volume 0.0
UXI1 On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:07 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

cyclacel pharmaceuticals inc (UXI1) Snapshot

Open
€0.52
Previous Close
€0.52
Day High
€0.52
Day Low
€0.52
52 Week High
02/17/14 - €3.00
52 Week Low
01/27/15 - €0.51
Market Cap
11.9M
Average Volume 10 Days
90.0
EPS TTM
--
Shares Outstanding
23.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CYCLACEL PHARMACEUTICALS INC (UXI1)

Related News

No related news articles were found.

cyclacel pharmaceuticals inc (UXI1) Related Businessweek News

No Related Businessweek News Found

cyclacel pharmaceuticals inc (UXI1) Details

Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops and commercializes mechanism-targeted drugs to treat human cancers and other serious diseases. The company’s oncology development programs include sapacitabine, an orally-available nucleoside analogue that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and seliciclib, an orally-available 2nd generation CDK inhibitor that selectively inhibits a spectrum of enzyme targets comprising CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its other oncology development programs comprise CYC065, an orally-available 2nd generation CDK-2, -5, -9 inhibitor that helps in cancer cell growth, metastatic spread, and DNA damage repair; CYC140, an orally-available small molecule inhibitor of polo-like kinase 1; and Sapacitabine + Seliciclib, which is in Phase I trials for the treatment of cancer. The company’s non-oncology programs comprise cell cycle inhibitors for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

18 Employees
Last Reported Date: 03/26/14
Founded in 1992

cyclacel pharmaceuticals inc (UXI1) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $713.4K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $463.1K
Chief Medical Officer and Vice President of C...
Total Annual Compensation: $442.4K
Compensation as of Fiscal Year 2013.

cyclacel pharmaceuticals inc (UXI1) Key Developments

Cyclacel Pharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 03:30 PM

Cyclacel Pharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 03:30 PM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States. Speakers: Spiro Rombotis, Chief Executive Officer, President and Executive Director.

Cyclacel Pharmaceuticals, Inc. - Special Call

to discuss the company's plans with regard to SEAMLESS

Cyclacel Pharmaceuticals, Inc. Announces Enrollment of 486 Patients Continuation to Final Analysis and Recommendations of the Independent Data and Safety Monitoring Board of Phase 3 SEAMLESS Study

Cyclacel Pharmaceuticals, Inc. announced enrollment of 486 patients, continuation to final analysis and recommendations of the independent Data and Safety Monitoring Board (DSMB) of the Company's Phase 3 SEAMLESS study of oral sapacitabine capsules in acute myeloid leukemia (AML). All patients will continue to be followed up until mature data become available for final analysis. The DSMB conducted its planned interim analysis for futility after 247 events and the final safety review of 470 randomized patients. The DSMB found no safety concerns. However, the planned futility boundary has been crossed and the DSMB determined that based on available interim data, it would be unlikely for the study to reach statistically significant improvement in survival. The DSMB saw no reasons why patients should discontinue treatment on their assigned arm and recommended that recruited patients stay on treatment. The interim analysis for futility is primarily driven by the deaths within the first 6 months of patients entering into the trial. Of 247 deaths in SEAMLESS, 173 (70%) have occurred in the first 6 months. This means that the survival curves beyond 6 months are poorly estimated at this time. Furthermore, follow up of European patients is significantly shorter than that of US patients due to the fact that the study opened for European accrual in April 2014. It is important to have complete follow up of all patients to ensure that a potential treatment effect beyond 6 months is not missed. The Company remains blinded and in accordance with the DSMB's recommendations, will follow-up patients as per the study protocol until the prespecified 424 events have been observed. This is estimated to occur between the second half of 2015 and the first half of 2016. The Company has adequate financial resources to reach beyond the later time point in this estimate. Depending on the results from the final data, the Company may meet with regulatory authorities in Europe and the U.S. to discuss registration submissions for sapacitabine in this indication. The Company wishes to draw investors' attention to the precedent of decitabine's European approval in AML in a similar population based on a Phase 3 study which did not reach statistical significance comparing intravenous decitabine with intravenous chemotherapy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UXI1:GR €0.52 EUR 0.00

UXI1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for UXI1.
View Industry Companies
 

Industry Analysis

UXI1

Industry Average

Valuation UXI1 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.7x
Price/Book 0.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYCLACEL PHARMACEUTICALS INC, please visit www.cyclacel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.